- Home
- PBYI vs RMNI Comparison
PBYI vs RMNI Comparison
Compare PBYI & RMNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBYI
- RMNI
- Stock Information
- Founded
- PBYI 2010
- RMNI 2005
- Country
- PBYI United States
- RMNI United States
- Employees
- PBYI N/A
- RMNI N/A
- Industry
- PBYI Biotechnology: Pharmaceutical Preparations
- RMNI Business Services
- Sector
- PBYI Health Care
- RMNI Consumer Discretionary
- Exchange
- PBYI Nasdaq
- RMNI Nasdaq
- Market Cap
- PBYI 164.3M
- RMNI 368.8M
- IPO Year
- PBYI N/A
- RMNI N/A
- Fundamental
- Price
- PBYI $3.45
- RMNI $5.24
- Analyst Decision
- PBYI Strong Buy
- RMNI Buy
- Analyst Count
- PBYI 1
- RMNI 2
- Target Price
- PBYI $7.00
- RMNI $6.00
- AVG Volume (30 Days)
- PBYI 307.3K
- RMNI 489.2K
- Earning Date
- PBYI 07-31-2025
- RMNI 07-31-2025
- Dividend Yield
- PBYI N/A
- RMNI N/A
- EPS Growth
- PBYI 143.51
- RMNI N/A
- EPS
- PBYI 0.77
- RMNI N/A
- Revenue
- PBYI $232,709,000.00
- RMNI $426,212,000.00
- Revenue This Year
- PBYI N/A
- RMNI $1.38
- Revenue Next Year
- PBYI N/A
- RMNI $3.97
- P/E Ratio
- PBYI $4.43
- RMNI N/A
- Revenue Growth
- PBYI 2.68
- RMNI N/A
- 52 Week Low
- PBYI $2.23
- RMNI $1.53
- 52 Week High
- PBYI $4.13
- RMNI $5.38
- Technical
- Relative Strength Index (RSI)
- PBYI 50.12
- RMNI 77.27
- Support Level
- PBYI $3.26
- RMNI $3.87
- Resistance Level
- PBYI $3.68
- RMNI $5.38
- Average True Range (ATR)
- PBYI 0.12
- RMNI 0.30
- MACD
- PBYI 0.00
- RMNI 0.15
- Stochastic Oscillator
- PBYI 52.90
- RMNI 94.08
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
About RMNI Rimini Street Inc. (DE)
Rimini Street Inc and its subsidiaries are providers of end-to-end enterprise software support, products, and services. The Company offers a comprehensive family of unified solutions to run, manage, support, customize, configure, connect, protect, monitor, and optimize clients' enterprise applications, database, and technology software platforms. The Company derives revenues from clients by providing subscription support services for enterprise resource planning, customer relationship management, product lifecycle management database, and technology software systems. Geographically, the company generates the majority of its revenue from the United States of America and the International market.